{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T09:08:01Z","timestamp":1784797681730,"version":"3.55.0"},"reference-count":10,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100010476","name":"Tata Memorial Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010476","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.euo.2020.03.004","type":"journal-article","created":{"date-parts":[[2020,5,29]],"date-time":"2020-05-29T01:38:43Z","timestamp":1590716323000},"page":"826-828","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Bacillus Calmette-Gu\u00e9rin Retains Clinically Relevant Viability for up to 72 Hours After Reconstitution: Potential Implications for Clinical Practice in Times of Shortage"],"prefix":"10.1016","volume":"4","author":[{"given":"Nathan","family":"Brooks","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Supriya","family":"Nagaraju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Matulay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang-Yang","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish M.","family":"Kamat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2020.03.004_bib0005","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline","volume":"196","author":"Chang","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2020.03.004_bib0010","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.euf.2018.06.018","article-title":"Manufacturing and the market: Rationalizing the shortage of bacillus Calmette-Gu\u00e9rin","volume":"4","author":"Bandari","year":"2018","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euo.2020.03.004_bib0015","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.eururo.2012.10.039","article-title":"Final results of an EORTC-GU Cancers Group randomized study of maintenance bacillus Calmette-Gu\u00e9rin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance","volume":"63","author":"Oddens","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2020.03.004_bib0020","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.euo.2019.06.011","article-title":"How to treat multifocal Ta high-grade disease if Bacillus Calmette-Gu\u00e9rin is unavailable","volume":"3","author":"Witjes","year":"2020","journal-title":"Eur Urol Onc"},{"key":"10.1016\/j.euo.2020.03.004_bib0025","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S0022-5347(17)46976-X","article-title":"Intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: effect of bacillus Calmette-Guerin viability on treatment results","volume":"134","author":"Kelley","year":"1985","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2020.03.004_bib0030","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1080\/00480169.2011.595905","article-title":"Longevity of Mycobacterium bovis in brushtail possum (Trichosurus vulpecula) carcasses, and contact rates between possums and carcasses","volume":"59","author":"Barron","year":"2011","journal-title":"N Zeal Vet J"},{"key":"10.1016\/j.euo.2020.03.004_bib0035","first-page":"608","article-title":"Stability of reconstituted freeze-dried bacille Calmette-Guerin used for intravesical immunotherapy for bladder cancer","volume":"5","author":"Conly","year":"1998","journal-title":"Can J Urol"},{"key":"10.1016\/j.euo.2020.03.004_bib0040","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1016\/S0264-410X(99)00023-7","article-title":"Development of a tetrazolium salt assay for rapid determination of viability of BCG vaccines","volume":"17","author":"Kairo","year":"1999","journal-title":"Vaccine"},{"key":"10.1016\/j.euo.2020.03.004_bib0045","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1016\/S0022-5347(01)68241-7","article-title":"Pharmacological biocompatibility between intravesical preparations of BCG and interferon-alpha 2B","volume":"158","author":"Downs","year":"1997","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2020.03.004_bib0050","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1016\/j.vaccine.2004.01.050","article-title":"Report on a WHO consultation on the characterisation of BCG strains, Imperial College, London 15\u201316 December 2003","volume":"22","author":"Corbel","year":"2004","journal-title":"Vaccine"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931120300468?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931120300468?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T15:47:05Z","timestamp":1762876025000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931120300468"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":10,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S2588931120300468"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2020.03.004","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bacillus Calmette-Gu\u00e9rin Retains Clinically Relevant Viability for up to 72 Hours After Reconstitution: Potential Implications for Clinical Practice in Times of Shortage","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2020.03.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}